Drug Approval | October 20, 2023
USFDA approves Pfizer’s Velsipity for adults with Ulcerative Colitis
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Profit after tax (before exceptional items) up 23% to Rs 215 crores
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Subscribe To Our Newsletter & Stay Updated
